While VISTA blockade significantly enhanced CD8 + T cell activation and increased macrophage pro-inflammatory cytokine expression, it did not significantly reduce primary tumour growth or metastatic burden, although we can already appreciate a trend towards a reduced metastatic burden in the lungs of mice treated with only one dose of anti-VISTA antibody. Here, VSIR is linked to neoplasm.